Physician profile
Peter Alamir
NPI 1073216743
$500.78
in general payments reported to CMS, 2019-2025
11 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $226 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $202.67 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Pharming Healthcare, INC. | $82.16 | 2024-2025 | Ruconest |
| Pfizer INC. | $42.21 | 2024-2025 | |
| Csl Behring | $33.63 | 2024 | Hizentra |
| Genzyme Corporation | $25.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.62 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $21.55 | 2024 | |
| Genentech USA, INC. | $19.74 | 2025 | Xolair |
| Lundbeck LLC | $18.08 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $16.98 | 2024 | Eliquis |
| Novo Nordisk INC | $14.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Alamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.